Catalyst Wire Dossier Catalyst Wire Dossier

Vixarelimab

vixarelimab · Genentech, Inc.
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Vixarelimab, covering 2026-01-13 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis [Phase 1, Phase 2]

See pricing